These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9678800)

  • 1. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
    Schots R; Kaufman L; Van Riet I; Lacor P; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation.
    Schots R; Van Riet I; Othman TB; Trullemans F; De Waele M; Van Camp B; Kaufman L
    Bone Marrow Transplant; 2002 Oct; 30(7):441-6. PubMed ID: 12368956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.
    Schots R; Kaufman L; Van Riet I; Ben Othman T; De Waele M; Van Camp B; Demanet C
    Leukemia; 2003 Jun; 17(6):1150-6. PubMed ID: 12764383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.
    Min CK; Kim SY; Eom KS; Kim YJ; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2006 Mar; 37(5):493-8. PubMed ID: 16435015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.
    Mehta J; Powles R; Horton C; Milan S; Singhal S; Treleaven J
    Bone Marrow Transplant; 1995 Jun; 15(6):853-8. PubMed ID: 7581080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
    Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
    Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities.
    Sutton L; Kuentz M; Cordonnier C; Blaise D; Devergie A; Guyotat D; Leblond V; Flesch M; Bordigoni P; Attal M
    Bone Marrow Transplant; 1993 Dec; 12(6):583-9. PubMed ID: 8136742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
    Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
    Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients.
    Hahn T; Rondeau C; Shaukat A; Jupudy V; Miller A; Alam AR; Baer MR; Bambach B; Bernstein Z; Chanan-Khan AA; Czuczman MS; Slack J; Wetzler M; Mookerjee BK; Silva J; McCarthy PL
    Bone Marrow Transplant; 2003 Aug; 32(4):405-10. PubMed ID: 12900777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin.
    Bacigalupo A; Oneto R; Bruno B; Soracco M; Lamparelli T; Gualandi F; Occhini D; Raiola A; Mordini N; Berisso G; Bregante S; Dini G; Lombardi A; Lint MV; Brand R
    Bone Marrow Transplant; 1999 Sep; 24(6):653-9. PubMed ID: 10490732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
    Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
    Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation.
    Cornelissen JJ; Fibbe WE; Schattenberg AV; Petersen EJ; Willemze R; de Witte TJ; Löwenberg B; Verdonck LF; vd Biezen A; Brand R
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S66-70. PubMed ID: 9712499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.